Episode Details
Back to Episodes
The Future of Aesthetics: mTOR Science, GLP-1s, and Longevity Biology with Brent Saunders
Description
Are you ready to separate genuine longevity science from aesthetic marketing hype? In this episode of Beauty Bytes, I am joined by Brent Saunders, one of the most influential executives in the pharmaceutical and medical aesthetics industries. With over 25 years of experience, Brent is best known for his tenure as Chairman and CEO of Allergan—where he built iconic brands like Botox, Juvéderm, and CoolSculpting—as well as serving two terms as CEO of Bausch + Lomb and acting as Chairman of The Beauty Health Company (HydraFacial).
We discuss the massive paradigm shift in aesthetic medicine—moving from simply correcting visible wrinkles to targeting the cellular biology of aging. Brent unpacks the rigorous standard of evidence required for true pharmaceutical breakthroughs, challenging the aesthetic industry's reliance on animal studies and unproven claims surrounding trending ingredients like exosomes and unregulated peptides.
We dive deep into the science of mTOR inhibition and how his new co-founded company, Rapologix, is revolutionizing skin longevity. Brent explains why broad mTOR inhibitors like rapamycin act as a biological "sledgehammer," and how REQ's proprietary RLX201 molecule selectively inhibits mTORC1 while allowing mTORC2 expression to successfully reset and rejuvenate skin fibroblasts. We also discuss the massive aesthetic ripple effects of GLP-1 medications—including the resulting boom in facelifts and skin-tightening procedures to combat "Ozempic face" and muscle loss—and why Brent believes the foundational triad of sleep, diet, and exercise will always outperform any biohacking shortcut.
Guest Information: Brent Saunders is a renowned healthcare executive, the former CEO of Allergan and Bausch + Lomb, the Chairman of The Beauty Health Company, and the co-founder of Rapologix Health. You can connect with him on Instagram at @brentlsaunders or visit his website at brentsaunders.com.